The variety of genetic testing approaches used for ovarian as well as breast cancer has markedly risen in recent times, but a lot of patients are not tested. As a result, variants of unidentified relevance (VUS), specifically among minorities, prevail, according to the outcomes of a research study published in the Journal of Clinical Oncology.
The research examined hereditary screening trends and causes in 187,535 breast cancer patients as well as 14,689 women with ovarian cancer. Every one of whom was detected in between 2013-2017. The outcomes revealed that the examinations were just done in 34% of women with ovarian cancers and 25% of breast cancer patients. Although the number of genetics tested boosted by 28% each year and also the discovery rates of VUS additionally enhanced significantly, the variety of patients evaluated boosted by only 2% every year. Among breast cancer patients who were detected in early 2013, 8.5% had a VUS-only outcome compared to 22% in late 2017. In women with ovarian cancer, the rate of VUS-only results was 8% in those who received a “Diagnosed” with their detection in very early 2013 as well as 28% in late 2017.
The rate of VUS-only results was discovered to be significantly greater in racial minority cohorts with ovarian or breast cancer compared to white patients. The multivariate analysis identified race or ethnic background as a significant predictor of VUS-only outcomes (P <0.001).
The majority of the pathogenic variants of breast and also ovarian cancers have been recognized in 20 genetic grouping results. The research study’s authors stated that focusing exclusively on these 20 results might make the most of the clinically relevant results of pathogenic versions while minimizing VUS results, specifically in patients with racial or ethnic minorities.
“Quality improvement initiatives need to concentrate on shutting the genetic screening space in the specified individuals … as opposed to including much more genes per test,” the study writers created.
Kurian AW, Ward KC, Abrahamse P. et al. Time trends in receiving germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019. J Clin Oncol. Published online on February 9, 2021. doi: 10.1200 / JCO.20.02785